140 related articles for article (PubMed ID: 8616809)
1. p53 gene mutation in thyroid carcinoma.
Ho YS; Tseng SC; Chin TY; Hsieh LL; Lin JD
Cancer Lett; 1996 May; 103(1):57-63. PubMed ID: 8616809
[TBL] [Abstract][Full Text] [Related]
2. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas.
Dobashi Y; Sugimura H; Sakamoto A; Mernyei M; Mori M; Oyama T; Machinami R
Diagn Mol Pathol; 1994 Mar; 3(1):9-14. PubMed ID: 8162258
[TBL] [Abstract][Full Text] [Related]
3. p53 mutations in childhood thyroid tumours from Belarus and in thyroid tumours without radiation history.
Smida J; Zitzelsberger H; Kellerer AM; Lehmann L; Minkus G; Negele T; Spelsberg F; Hieber L; Demidchik EP; Lengfelder E; Bauchinger M
Int J Cancer; 1997 Dec; 73(6):802-7. PubMed ID: 9399655
[TBL] [Abstract][Full Text] [Related]
4. Genetic alterations in thyroid tumor progression: association with p53 gene mutations.
Ito T; Seyama T; Mizuno T; Tsuyama N; Hayashi Y; Dohi K; Nakamura N; Akiyama M
Jpn J Cancer Res; 1993 May; 84(5):526-31. PubMed ID: 8100564
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.
Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA
Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289
[TBL] [Abstract][Full Text] [Related]
6. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
Fagin JA; Matsuo K; Karmakar A; Chen DL; Tang SH; Koeffler HP
J Clin Invest; 1993 Jan; 91(1):179-84. PubMed ID: 8423216
[TBL] [Abstract][Full Text] [Related]
7. Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines.
Jossart GH; Epstein HD; Shaver JK; Weier HU; Greulich KM; Tezelman S; Grossman RF; Siperstein AE; Duh QY; Clark OH
J Clin Endocrinol Metab; 1996 Oct; 81(10):3498-504. PubMed ID: 8855792
[TBL] [Abstract][Full Text] [Related]
8. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.
Donghi R; Longoni A; Pilotti S; Michieli P; Della Porta G; Pierotti MA
J Clin Invest; 1993 Apr; 91(4):1753-60. PubMed ID: 8473515
[TBL] [Abstract][Full Text] [Related]
9. Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas.
Shi Y; Zou M; Farid NR; al-Sedairy ST
Br J Cancer; 1996 Nov; 74(9):1336-41. PubMed ID: 8912526
[TBL] [Abstract][Full Text] [Related]
10. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
11. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
12. G --> A mutation of ras genes and infrequent p53 gene mutation in rat transplantable thyroid carcinoma lines from tumors induced in vivo by N-bis(2-hydroxypropyl)nitrosamine.
Kitahori Y; Naitoh H; Konishi N; Fukushima M; Ohnishi T; Hiasa Y
Cancer Lett; 1996 Feb; 100(1-2):55-62. PubMed ID: 8620454
[TBL] [Abstract][Full Text] [Related]
13. Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours.
Wright PA; Lemoine NR; Goretzki PE; Wyllie FS; Bond J; Hughes C; Röher HD; Williams ED; Wynford-Thomas D
Oncogene; 1991 Sep; 6(9):1693-7. PubMed ID: 1923534
[TBL] [Abstract][Full Text] [Related]
14. Mutations of p53 in thyroid carcinoma with an insular component.
Takeuchi Y; Daa T; Kashima K; Yokoyama S; Nakayama I; Noguchi S
Thyroid; 1999 Apr; 9(4):377-81. PubMed ID: 10319944
[TBL] [Abstract][Full Text] [Related]
15. Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutation in two out of fifty-six thyroid tumours.
Salvatore D; Celetti A; Fabien N; Paulin C; Martelli ML; Battaglia C; Califano D; Monaco C; Viglietto G; Santoro M; Fusco A
Eur J Endocrinol; 1996 Feb; 134(2):177-83. PubMed ID: 8630516
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma.
Dobashi Y; Sakamoto A; Sugimura H; Mernyei M; Mori M; Oyama T; Machinami R
Am J Surg Pathol; 1993 Apr; 17(4):375-81. PubMed ID: 7684202
[TBL] [Abstract][Full Text] [Related]
17. Mutation profile of the p53, fhit, p16INK4a/p19ARF and H-ras genes in Indian breast carcinomas.
Kannan K; Krishnamurthy J; Feng J; Nakajima T; Tsuchida N; Shanmugam G
Int J Oncol; 2000 Nov; 17(5):1031-5. PubMed ID: 11029509
[TBL] [Abstract][Full Text] [Related]
18. [Relationship of p53 gene mutation with pathological characteristics and prognosis of thyroid carcinoma].
Song Y; Wang L; Huang G; Yuan S; Xiao L
Hua Xi Yi Ke Da Xue Xue Bao; 2000 Sep; 31(3):298-9, 314. PubMed ID: 12545813
[TBL] [Abstract][Full Text] [Related]
19. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas.
Hernandez L; Fest T; Cazorla M; Teruya-Feldstein J; Bosch F; Peinado MA; Piris MA; Montserrat E; Cardesa A; Jaffe ES; Campo E; Raffeld M
Blood; 1996 Apr; 87(8):3351-9. PubMed ID: 8605352
[TBL] [Abstract][Full Text] [Related]
20. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland.
Ito T; Seyama T; Mizuno T; Tsuyama N; Hayashi T; Hayashi Y; Dohi K; Nakamura N; Akiyama M
Cancer Res; 1992 Mar; 52(5):1369-71. PubMed ID: 1737400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
